Reappraisal of XRCC1 Arg194Trp polymorphism and glioma risk: a cumulative meta-analysis

Jun-Ti Lu\textsuperscript{1,*}, Ai-Ping Deng\textsuperscript{1,*}, Juan Song\textsuperscript{2,*}, Li Zhang\textsuperscript{1}, Jie Luo\textsuperscript{1}

\textsuperscript{1}Department of Neurosurgery, Taihe Hospital, Hubei University of Medicine, Shiyan 442000, China
\textsuperscript{2}Department of Clinical Laboratory, Taihe Hospital, Hubei University of Medicine, Shiyan 442000, China
\textsuperscript{*}Jun-Ti Lu, Ai-Ping Deng and Juan Song are co-first authors

Correspondence to: Jie Luo, email: luotaihe001@163.com

Keywords: XRCC1, X-ray repair cross-complementing group 1, polymorphism, glioma, meta-analysis

Received: December 08, 2016  Accepted: January 11, 2017  Published: February 16, 2017

ABSTRACT

The association between XRCC1 Arg194Trp polymorphism and glioma risk were inconsistent from published meta-analyses and epidemiological studies. Hence, we performed this updated and cumulative meta-analysis to reappraisal this relationship. PubMed, Embase, CBM (Chinese Biomedical Database), and CNKI (China National Knowledge Internet) databases were comprehensively searched up to August 13, 2016 (updated on December 22, 2016). After study selection and data extraction from eligible studies, the association was evaluated by odds ratios (ORs) and its 95% confidence intervals (95%CIs) using Comprehensive Meta-Analysis software. Finally 16 case-control studies involving 7011 patients and 9519 healthy controls were yielded. The results indicated that XRCC1 Arg194Trp polymorphism was significantly correlated with the increased risk of glioma [Trp vs. Arg: OR = 1.18(1.05-1.34); TrpTrp vs. ArgArg: OR = 1.66(1.31-2.12); ArgTrp vs. ArgArg: OR = 1.34(1.02-1.77); TrpTrp vs. ArgArg+ArgTrp: OR = 1.47(1.26-1.72); TrpTrp+ArgTrp vs. ArgArg: OR = 1.17(1.01-1.35)]. Cumulative analysis showed the results changed from non-significant to significant when new studies accumulated, and sensitivity analysis indicated the results were stable. Subgroup analysis showed the significant association existed in Asians but not in Caucasians. Current evidence indicated that XRCC1 Arg194Trp polymorphism was associated with increased risk for glioma, especially in Asians; however, relevant studies involving other ethnic groups are required to validate our findings in further.

INTRODUCTION

Glioma is the most common and the worst prognosis on primary central nervous system (CNS) tumors, making up approximately 30 % of all brain and CNS tumors and 80 % of all malignant brain tumors [1, 2]. However, the etiology of glioma is largely unknown. The radiation exposure and certain genetic syndromes are well-defined risk factors for malignant glioma [3]. The base excision repair (BER), nucleotide excision repair (NER), mismatch repair (MMR), and double strand break repair (DSBR) are the four major DNA repair pathways [4]. X-ray repair cross-complementing group 1 (XRCC1) gene, which is located on chromosome 19q 13.2–13.3 with a length of 33 kilobases, is one of the DNA repair genes encoding a scaffolding protein that participates in BER pathway [5, 6]. There are more than 300 validated single nucleotide polymorphisms (SNPs) in the XRCC1 gene in the dbSNP database; thereinto, Arg399Gln (rs25487), Arg280His (rs25489), and Arg194Trp (rs1799782) are the three extensively studied polymorphisms.

From 2012 to 2016, there are 14 meta-analyses [7–20] published to estimate the association between XRCC1 Arg194Trp polymorphism and glioma risk, but the results are contradictory (Supplementary Table 1). Hence, it is still unclear whether XRCC1 Arg194Trp polymorphism is associated with risk of glioma. In 2014, Adel Fahmideh et al [21] conducted a systematic review and meta-analysis to investigate the association between DNA repair gene polymorphisms (ERCC1}
rs3212986, ERCC2/XPD rs13181, MGMT rs12917, PARP1 rs1136410, and XRCC1 rs25487) and risk of glioma. Obviously, XRCC1 rs1799782 polymorphism is not included. Moreover, there are many relevant studies which are published after the previous 14 meta-analyses and also yield inconsistent results. Therefore, we performed this updated and cumulative meta-analysis [22, 23] to explore the more precise association between Arg194Trp polymorphism and glioma risk. Subgroup analyses were also performed according to Caucasian and Asian populations to investigate ethnicity-specific effects; the subgroup analyses based on the source of controls and the HWE for controls were conducted as well.

RESULTS

Study selection and characteristics

The primary search yielded 208 potentially related publications and finally 16 case-control studies involving 7011 patients and 9519 healthy controls were included [24–39]. Figure 1 shows the study selection process. Of these studies, five dealt with probands of Caucasian origin [24–27, 30] and eleven referred to Asian origin [28, 29, 31–39]; five studies were out of Hardy Weinberg Equilibrium (HWE) [28, 30, 31, 34, 37]. Table 1 lists the main characteristics of identified studies.

Meta-analysis

Table 2 demonstrates the results of overall and subgroup analyses. Overall, XRCC1 Arg194Trp polymorphism was significantly associated with increased risk of glioma under all five genetic models: the allele comparison, homozygote comparison, heterozygote comparison, recessive model, and dominant model [for Trp vs. Arg: odds ratio (OR) and its 95% confidence interval (95%CI) = 1.18(1.05-1.34), \( I^2 = 73.96 \% \); for TrpTrp vs. ArgArg: OR = 1.66(1.31-2.12), \( I^2 = 45.84 \% \), Figure 2; for ArgTrp vs. ArgArg: OR = 1.34(1.02-1.77), \( I^2 = 91.01 \% \); for TrpTrp vs. ArgArg+ArgTrp: OR = 1.47(1.26-1.72), \( I^2 = 13.64 \% \), TrpTrp+ArgTrp vs. ArgArg: OR = 1.17(1.01-1.35), \( I^2 = 72.60 \% \), respectively].

The cumulative meta-analysis accumulated the studies according to the publication year which displayed that the association change from non-significant to significant with new studies accumulated, and the CIs became increasing narrower (Figure 3 and Supplementary Figure 1 to Figure 4). Sensitivity analysis indicated that the overall analysis was not influenced by any single study (Figure 4).

In the subgroup analysis for ethnicity, no significant association was found in Caucasians under all five genetic models, but significantly increased risk was observed in Asians under for contrasts (Trp vs.
Arg, TrpTrp vs. ArgArg, TrpTrp+ArgTrp vs. ArgArg, and TrpTrp vs. ArgArg+ArgTrp). After stratified analysis by source of controls, significant results were found both in hospital-based (Trp vs. Arg, TrpTrp vs. ArgArg, TrpTrp+ArgTrp vs. ArgArg, and TrpTrp vs. ArgArg+ArgTrp) and significant results for population-based controls (TrpTrp vs. ArgArg). Significant association existed in the studies conforming to HWE under two genetic models (TrpTrp vs. ArgArg and TrpTrp vs. ArgArg+ArgTrp) and in the studies deviating from HWE under all five genetic models.

### DISCUSSION

The first study on the association between XRCC1 Arg194Trp polymorphism and glioma risk was performed by Liu et al in 2007 [36], involving 756 cases and 754 controls from Chinese, and the results indicated no significant association between XRCC1 Arg194Trp polymorphisms and glioma risk. In 2012, Zhang et al conducted a meta-analysis to explore the role of XRCC1 Arg194Trp polymorphism in glioma risk based on 4 case-control studies [24, 27–29], and the results indicated that there was no remarkable association between them [8]. Then the findings from a meta-analysis by Sun et al. based on 7 studies were not totally similar to the above-mentioned results [7]. In 2013, Li et al. conducted a meta-analysis of 5 case-control studies, which revealed that XRCC1 Arg194Trp polymorphism might associated with risk of glioma [10]. The following meta-analysis performed by Jiang et al. of 6 case-control studies

### Table 1: Characteristics of included studies in the meta-analysis

| References | Country (Ethnicity) | Case | Source of control | Control | Genotyping method | HWE |
|------------|---------------------|------|-------------------|---------|-------------------|-----|
| Liu 2007   | China (Asian)       | 756  | 371 308 77       | 754 375 305 74 | TaqMan | Yes |
| Kiuru 2008 | European countries  | 700  | 626 71 3        | 1556 1377 177 2 | PCR-RFLP | Yes |
| Liu 2009   | USA (Caucasian)     | 210  | 180 29 1        | 365 310 52 3 | MassARRAY | Yes |
| McKean-Cowdin 2009 | USA (Caucasian) | 1022 | 842 177 3       | 2022 1664 352 6 | TaqMan | Yes |
| Rajaraman 2011 | USA (Caucasian)   | 342  | 304 38 0       | 468 394 73 1 | TaqMan | Yes |
| Hu 2011    | China (Asian)       | 127  | 71 38 18       | 249 163 64 22 | PCR-CTPP | No |
| Zhou 2011  | China (Asian)       | 271  | 145 112 14      | 289 159 117 13 | TaqMan | Yes |
| Custodio 2011 | Brazil (Caucasian) | 80   | 15 31 34       | 100 67 4 29 | PCR-RFLP | No |
| Wang 2012  | China (Asian)       | 624  | 376 218 30      | 580 355 205 20 | PCR-RFLP | Yes |
| Liu 2012   | China (Asian)       | 444  | 294 105 45      | 442 334 89 19 | MassARRAY | No |
| Luo 2013   | China (Asian)       | 297  | 204 63 30       | 415 297 96 22 | MassARRAY | Yes |
| Pan 2013   | China (Asian)       | 443  | 301 116 27      | 443 327 101 15 | MassARRAY | No |
| Xu 2014    | China (Asian)       | 886  | 525 301 60      | 886 540 311 35 | PCR-RFLP | Yes |
| Gao 2014   | China (Asian)       | 326  | 235 73 18       | 376 279 84 13 | MassARRAY | No |
| Li 2014    | China (Asian)       | 368  | 183 171 16      | 346 175 151 20 | PCR-RFLP | Yes |
| Fan 2016   | China (Asian)       | 115  | 31 58 26       | 228 82 109 37 | PCR-RFLP | Yes |

PB, population-based; HB, hospital-based; Mixed, population and hospital based; HWE, Hardy Weinberg Equilibrium

Arg, TrpTrp vs. ArgArg, TrpTrp+ArgTrp vs. ArgArg, and TrpTrp vs. ArgArg+ArgTrp). After stratified analysis by source of controls, significant results were found both in hospital-based (Trp vs. Arg, TrpTrp vs. ArgArg, TrpTrp+ArgTrp vs. ArgArg, and TrpTrp vs. ArgArg+ArgTrp) and significant results for population-based controls (TrpTrp vs. ArgArg). Significant association existed in the studies conforming to HWE under two genetic models (TrpTrp vs. ArgArg and TrpTrp vs. ArgArg+ArgTrp) and in the studies deviating from HWE under all five genetic models.

### Publication bias

As shown in Figure 5, no obvious publication bias was found. The Egger’s test also showed no evidence of publication bias (Trp vs. Arg: p = 0.22; TrpTrp vs. ArgArg: p = 0.83; ArgTrp vs. ArgArg: p = 0.12; TrpTrp+ArgTrp vs. ArgArg: p = 0.06; TrpTrp vs. ArgArg+ArgTrp: p = 0.97).
Table 2: Results of overall and subgroups analyses of pooled ORs and 95% CIs

| No. | Trp vs. Arg | OR (95%CI) | p for OR | F(%) | OR (95%CI) | p for OR | F(%) | OR (95%CI) | p for OR | F(%) | OR (95%CI) | p for OR | F(%) |
|-----|-------------|------------|----------|------|------------|----------|------|------------|----------|------|------------|----------|------|
| Overall | 16 | 1.18 (1.05-1.34) | 0.01 | 73.96 (1.31-2.12) | 0.04 | 4.58 (4.02-5.17) | 1.34 | <0.01 | 91.01 (1.01-1.35) | 0.04 | 72.60 (1.26-1.72) | 1.47 | <0.01 | 13.64 |
| Ethnicity | | | | | | | | | | | | | | |
| Asian | 11 | 1.20 (1.08-1.32) | <0.01 | 47.86 (1.28-1.80) | 0.13 | 34.10 (0.97-1.91) | 1.36 | 0.07 | 91.64 (1.05-1.24) | <0.01 | 11.42 (1.24-1.72) | 1.46 | <0.01 | 31.72 |
| Caucasian | 5 | 1.15 (0.74-1.77) | 0.54 | 89.03 (0.69-5.36) | 0.21 | 50.25 (0.77-2.23) | 1.31 | 0.32 | 89.6 (0.76-2.12) | 0.37 | 90.3 (0.95-2.67) | 1.59 | 0.08 | 0 |
| Source of controls | | | | | | | | | | | | | | |
| Hospital | 11 | 1.19 (1.06-1.34) | <0.01 | 57.30 (1.40-2.05) | 0.41 | 2.92 (0.91-1.91) | 1.32 | 0.14 | 91.96 (1.02-1.30) | <0.01 | 39.80 (1.34-1.95) | 1.62 | <0.01 | 1.42 |
| Population | 3 | 1.45 (0.63-3.35) | 0.38 | 92.94 (2.11-7.90) | 0.08 | 40.26 (0.70-4.44) | 2.58 | 0.15 | 94.3 (0.60-5.86) | 0.28 | 94.4 (1.02-3.16) | 1.79 | 0.04 | 0 |
| Mixed | 2 | 1.01 (0.90-1.14) | 0.84 | 0.87 (0.75-1.47) | 1.05 | 0.79 (0.87-1.16) | 1.01 | 0.93 | 0 (0.88-1.16) | 1.01 | 0.89 (0.75-1.44) | 1.04 | 0.82 | 0 |
| HWE | | | | | | | | | | | | | | |
| Yes | 11 | 1.05 (0.98-1.13) | 0.13 | 16.78 (1.11-1.63) | 1.34 | 0.36 (0.86-1.68) | 8.87 | 1.20 | 92.48 (0.94-1.11) | 1.02 | 0.58 (1.09-1.58) | 1.31 | <0.01 | 10.13 |
| No | 5 | 1.65 (1.23-2.22) | <0.01 | 79.36 (1.79-3.65) | 2.41 | 0.18 (1.06-3.05) | 35.78 | 1.79 | 87.21 (1.16-2.83) | 1.81 | 0.01 (1.45-2.56) | 85.86 | 1.93 | <0.01 |

Egger’s test: 0.22; 0.83; 0.12; 0.06; 0.97

Figure 2: Forest plot for overall analysis in TrpTrp vs. ArgArg comparison.
indicated Arg194Trp polymorphism might have no influence on the susceptibility of glioma [9]. The fifth meta-analysis from Zhang et al [11] including 8 case-controls showed that Arg194Trp polymorphism increased the glioma risk. The meta-analysis from He et al in 2014 based on 8 studies showed Arg194Trp probably increased risk for glioma due to studies deviating from HWE in controls [16]. Another six meta-analyses indicated that

### Figure 3: Forest plot for cumulative analysis in TrpTrp vs. ArgArg comparison.

| Study name       | Cumulative statistics | Cumulative odds ratio (95% CI) |
|------------------|-----------------------|--------------------------------|
|                  | Point | Lower limit | Upper limit | Z-Value | p-Value |
| Liu 2007         | 1.05  | 0.74        | 1.49        | 0.28    | 0.78    |
| Kiuru 2008       | 1.31  | 0.54        | 3.17        | 0.60    | 0.55    |
| Liu 2009         | 1.08  | 0.77        | 1.52        | 0.45    | 0.65    |
| Mceean-Cowdin 2009 | 1.08 | 0.77        | 1.50        | 0.43    | 0.66    |
| Rajaraman 2010   | 1.07  | 0.77        | 1.48        | 0.38    | 0.71    |
| Custodio 2011    | 1.61  | 0.68        | 3.84        | 1.08    | 0.28    |
| Hu 2011          | 1.70  | 0.89        | 3.27        | 1.60    | 0.11    |
| Zhou 2011        | 1.61  | 0.94        | 2.77        | 1.74    | 0.08    |
| Wang 2012        | 1.58  | 1.02        | 2.44        | 2.06    | 0.04    |
| Liu 2012         | 1.71  | 1.14        | 2.57        | 2.59    | 0.01    |
| Luo 2013         | 1.75  | 1.22        | 2.50        | 3.06    | 0.00    |
| Pan 2013         | 1.77  | 1.28        | 2.44        | 3.49    | 0.00    |
| Xu 2014          | 1.76  | 1.34        | 2.33        | 4.02    | 0.00    |
| Gao 2014         | 1.75  | 1.36        | 2.26        | 4.31    | 0.00    |
| Li 2014          | 1.65  | 1.27        | 2.14        | 3.77    | 0.00    |
| Fan 2016         | 1.66  | 1.31        | 2.12        | 4.12    | 0.00    |

**Heterogeneity:** $Q = 27.69$, df($Q$) = 15.00, $p = 0.02$, I-squared = 45.04%

### Figure 4: Forest analysis for sensitivity analysis in TrpTrp vs. ArgArg comparison.

| Study name       | Statistics with study removed | Odds ratio (95% CI) with study removed |
|------------------|-------------------------------|---------------------------------------|
|                  | Point | Lower limit | Upper limit | Z-Value | p-Value |
| Liu 2007         | 1.78  | 1.40        | 2.25        | 4.77    | 0.00    |
| Kiuru 2008       | 1.64  | 1.29        | 2.10        | 3.96    | 0.00    |
| Liu 2009         | 1.68  | 1.32        | 2.15        | 4.17    | 0.00    |
| Mceean-Cowdin 2009 | 1.69 | 1.32        | 2.16        | 4.12    | 0.00    |
| Rajaraman 2010   | 1.68  | 1.31        | 2.14        | 4.14    | 0.00    |
| Custodio 2011    | 1.54  | 1.26        | 1.87        | 4.25    | 0.00    |
| Hu 2011          | 1.65  | 1.27        | 2.14        | 3.78    | 0.00    |
| Zhou 2011        | 1.70  | 1.32        | 2.19        | 4.09    | 0.00    |
| Wang 2012        | 1.69  | 1.30        | 2.20        | 3.91    | 0.00    |
| Liu 2012         | 1.59  | 1.24        | 2.03        | 3.70    | 0.00    |
| Luo 2013         | 1.64  | 1.26        | 2.13        | 3.71    | 0.00    |
| Pan 2013         | 1.64  | 1.27        | 2.13        | 3.75    | 0.00    |
| Xu 2014          | 1.65  | 1.26        | 2.17        | 3.65    | 0.00    |
| Gao 2014         | 1.67  | 1.29        | 2.16        | 3.86    | 0.00    |
| Li 2014          | 1.76  | 1.39        | 2.22        | 4.70    | 0.00    |
| Fan 2016         | 1.65  | 1.27        | 2.14        | 3.77    | 0.00    |

**Heterogeneity:** $Q = 27.69$, df($Q$) = 15.00, $p = 0.02$, I-squared = 45.04%
Arg194Trp polymorphisms might contribute to genetic susceptibility to glioma in the Chinese population [12, 14, 17–20]. Almost all published meta-analyses suggested that more large-scale, well-designed and population-based studies were required for further evaluation [7–19].

Obviously, their results are inconsistent (Supplementary Table 1). Nowadays, 16 case-control studies and have yielded inconsistent results (Figure 2). Meta-analysis is a useful tool to resolve the inconsistent results from single study, which has been broadly applied in epidemiological field [40–44]. Hence, we undertook this comprehensive meta-analysis to provide an updated approach on the overall relationship. The cumulative analysis was also used to evaluate the result influenced by sample sizes. In the end, our meta-analysis of 16 case-control studies indicated that XRCC1 Arg194Trp polymorphism probably was associated with increased risk of glioma, and the cumulative analysis suggested that the non-significant association would be change to significant if the sample sizes were enough. The subgroups analyses indicated that XRCC1 Arg194Trp polymorphism elevated disease risk in Asians, but not associated in Caucasians.

The results of our meta-analysis are opposed to the conclusions from previously six meta-analyses in overall population [7–10, 15, 16], which all indicated there was no association between XRCC1 Arg194Trp polymorphism and glioma risk. The major reason is that our meta-analysis included more studies than them; therefore, our meta-analysis is the most comprehensive one currently. In order to explore the influence of sample size on overall estimation, we conducted cumulative meta-analysis, which showed that the association became significant and the results were changed with the sample size cumulated (Figure 3). For the subgroup analysis, the results were varied; this might be also attributed to the sample sizes. Hence, relevant studies should be performed to further identify this relationship. Moreover, evidence indicates that ethnic-specific variation, different health care and socioeconomic class might exert an effect on the incidence of glioma [45]. When we performed subgroup analysis based on ethnicity, the results indicated no association in Caucasians but significant correlation in Asians, that might be attributable to the ethnic-specific background or insufficient sample size in Caucasians. Third, the results can be influenced by violations or deviations in HWE [46], which can explain the reason why the results were different of violation in HWE and deviation in HWE of our meta-analysis. Fourth, the source of controls also can impact the results. Generally, the population-based controls is more representative than hospital-based controls. In our meta-analysis, the result of hospital-based controls was different from that of population-based controls, and the former was similar with overall results whereas the latter was significant under two genetic

Funnel Plot of Standard Error by Log odds ratio

Figure 5: Funnel plot for the assessment of publication bias in Trp vs. Arg comparison.
models. This might indicate that the results of our meta-analysis were not influenced much by control source. Finally, the heterogeneity existed in the meta-analysis.

Our meta-analysis also is similar with the previous eight meta-analyses [7, 10, 11, 13, 17–20]. Therefore, our meta-analysis confirmed their results. We can observe that the association became significant from the study by Wang et al. [32] in 2012 (Figure 3), which was just the sixth included study of meta-analysis by Jiang et al. [9]. The meta-analyses by Zhang et al. [11], He et al. [14, 16], Feng et al. [12], Xu et al. [13], Li et al. [17], Qi et al. [18] and Li et al. [19] also included this study and all of these meta-analyses showed a significant association except the one by He et al. [16]. This proved the evidence that the result could be influenced by sample size. Hence, the next advantage of meta-analysis is that we performed the cumulative meta-analysis.

Our meta-analysis also has its limitations. First, the primary studies only provided data regarding Caucasians and Asians; therefore, more studies involving other ethnicities such as African should be conducted to validate our results. Besides, the important information such as histological types should be improved in further studies. Second, other factors that might contribute to the heterogeneity, such as age, histological types, gender could not be explored due to the lack of relevant data were in original studies. Third, for lacking recommended quality assessment tool [44], it was difficult to assess the quality of included studies and its influence; these potential biases might result in lack of replication of definite conclusions. Fourth, although no publication bias was detected and we tried our best to identify relevant publications, due to the limitations of languages and using permission of databases, only studies published in English and Chinese were included. So several databases were not searched and the studies in other languages were omitted, which might result in the occurrence of selection bias. Finally, this meta-analysis merely detected the association between the XRCC1 Arg194Trp polymorphism and glioma based on crude data. Therefore, the effects of gene - gene and gene - environment interactions were not mentioned in this research.

In conclusion, the results of the present meta-analysis suggest that the XRCC1 Arg194Trp polymorphism is associated with increased risk of glioma, especially for Asians. Of course, the results of our meta-analysis should be treated with caution, but unlike previous meta-analyses, we do not need to emphasize that relevant studies should be carried out for enlarging the sample sizes.

MATERIALS AND METHODS

This meta-analysis was reported following the recommended Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement [47].

Eligibility criteria

The study was included according to the following criteria: (1) the study assessed the association between the glioma and XRCC1 Arg194Trp polymorphism; (2) the study reported ORs and 95% CIs, or the number of individual genotypes in both case and control groups for their calculation; (3) the design was case-control or cohort study; and (4) the patients were microscopically diagnosed as glioma. In addition, if studies had the overlapping data, only the largest or the most complete one was included in the final analysis.

Search strategy

The PubMed, Embase, CBM (Chinese biomedical database), and CNKI (China National Knowledge Internet) databases were comprehensively searched up to August 13, 2016 (updated on December 22, 2016) using the following terms: (polymorphism OR mutation OR variant) AND (glioma OR “brain tumor” OR glioblastoma OR “glial cell tumors” OR “brain neoplasms”) AND (XRCC1 OR “x-ray cross complementing group 1”). Additional studies were manually searched from the references of all identified studies and the recent reviews.

Data extraction

Two authors selected studies according to the criteria listed above and extracted information from all eligible studies independently. The essential information contained the first author’s name, year of publication, country of origin, ethnicity of subjects, source of control, genotyping method, number of cases and controls and genotype frequency, ORs and its 95% CIs, and HWE for controls. All disagreements were resolved by consulting with a third author.

Data analysis

First, the heterogeneity among included studies was detected using $I^2$ statistics [48]. The value of $I^2 \leq 40\%$ was considered no substantive heterogeneity existed, so the fixed effect model was employed; otherwise, the random-effects model was used [49]. The OR and 95% CI were calculated for estimating the association between XRCC1 Arg194Trp polymorphism and glioma under the following common used five genetic models [50–53]: allele comparison (Trp vs. Arg), homozygote comparison (TrpTrp vs. ArgArg), heterozygote comparison (ArgTrp vs. ArgArg), dominant model (TrpTrp+ArgTrp vs. ArgArg), and recessive model (TrpTrp vs. ArgArg+ArgTrp), respectively. The subgroups analyses based on the ethnicity, source of controls, and the HWE for controls were performed to explore the potential source of heterogeneity among studies. Sensitivity analysis was applied by excluding each single study each time to
explore the stability of overall results. The cumulative meta-analysis was carried out to observe the change when with sample sizes were enlarged [22, 23]. The publication bias was detected by funnel plot analysis and the Egger linear regression test [54]. All the analyses were performed using the Comprehensive Meta-Analysis software, version 2.2 (Biostat, Englewood, New Jersey) [50, 52, 53] and all the p values were two-sided.

ACKNOWLEDGMENTS

The authors thank the authors of original studies which were included in our study.

CONFLICTS OF INTEREST

The authors declare that they have no conflict of interest.

GRANT SUPPORT

This research was supported (in part) by the Evidence-based Medicine Nursery Fund of Taihe Hospital (EBM2013017) without commercial or not-for-profit sectors. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. No additional external funding received for this study.

REFERENCES

1. Ohgaki H. Epidemiology of brain tumors. Methods Mol Biol. 2009; 472: 323-42.
2. Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta Neuropathol. 2005; 109: 93-108.
3. Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. JAMA. 2013; 310: 1842-50.
4. Wood RD, Mitchell M, Sgouros J, Lindahl T. Human DNA repair genes. Science. 2001; 291: 1284-9.
5. Caldecott KW, Tucker JD, Stanker LH, Thompson LH. Characterization of the XRCC1-DNA ligase III complex in vitro and its absence from mutant hamster cells. Nucleic Acids Res. 1995; 23: 4836-43.
6. Campalans A, Marsin S, Nakabeppu Y, O’Connor TR, Boiteux S, Radicella JP. XRCC1 interactions with multiple DNA glycosylases: a model for its recruitment to base excision repair. DNA Repair (Amst). 2005; 4: 826-35.
7. Sun JY, Zhang CY, Zhang ZJ, Dong YF, Zhang AL, Wang ZW, Mei XL. Association between XRCC1 gene polymorphisms and risk of glioma development: a meta-analysis. Asian Pac J Cancer Prev. 2012; 13: 4783-8.
8. Zhang L, Wang Y, Qiu Z, Luo J, Zhou Z, Shu W. The XRCC1 Arg194Trp polymorphism is not a risk factor for glioma: a meta-analysis involving 1,440 cases and 2,562 controls. Exp Ther Med. 2012; 4: 1057-62.
9. Liang L, Fang X, Bao Y, Zhou JY, Shen XY, Ding MH, Chen Y, Hu GH, Lu YC. Association between the XRCC1 polymorphisms and glioma risk: a meta-analysis of case-control studies. PLoS One. 2013; 8: e55597.
10. Li M, Zhou Q, Tu C, Jiang Y. A meta-analysis of an association between the XRCC1 polymorphisms and gliomas risk. J Neurooncol. 2013; 111: 221-8.
11. Zhang H, Liu H, Knauss JL. Associations between three XRCC1 polymorphisms and glioma risk: a meta-analysis. Tumour Biol. 2013.
12. Feng YZ, Liu YL, He XF, Wei W, Shen XL, Xie DL. Association between the XRCC1 Arg194Trp polymorphism and risk of cancer: evidence from 201 case-control studies. Tumour Biol. 2014; 35: 10677-97.
13. Xu C, Chen P, Liu W, Gu AH, Wang XR. Association between the XRCC1 Arg194Trp polymorphism and glioma risk: an updated meta-analysis. Asian Pac J Cancer Prev. 2014; 15: 7419-24.
14. He LW, Shi R, Jiang L, Zeng Y, Ma WL, Zhou JY. XRCC1 gene polymorphisms and glioma risk in Chinese population: a meta-analysis. PLoS One. 2014; 9: e111981.
15. Gu X, Sun H, Chang L, Sun R, Yang H, Zhang X, Cong X. Correlation between X-ray cross-complementing group 1 polymorphisms and the onset risk of glioma: A meta-analysis. Neural Regen Res. 2013; 8: 2468-77.
16. He H, Zeng F, Chen H, Chen Y. X-Ray Repair Cross-Complementing Group 1 (XRCC1) Genetic Polymorphisms and Risk of Glioma: A Meta-Analysis. Progress in Modern Biomedicine. 2014; 14: 5146-51.
17. Li J, Chen Q, Liu B, Yang J, Shao L, Wu T. Association between X-ray repair cross-complementing group 1 gene polymorphisms and glioma risk: a systematic review and meta-analysis based on 22 case-control studies. Int J Clin Exp Med. 2015; 8: 11863-80.
18. Qi L, Yu HQ, Zhang Y, Ding LJ, Zhao DH, Lv P, Wang WY, Xu Y. A Comprehensive Meta-analysis of Genetic Associations Between Key Polymorphic Loci in DNA Repair Genes and Glioma Risk. Mol Neurobiol. 2016.
19. Li J, Chen Q, Liu B, Shao L, Wu T, Yang JA. Research of association between X-ray repair cross-complementing 1 polymorphisms and glioma risk. Chinese Journal of Experimental Surgery. 2016; 33: 670-4.
20. Liu K, Jiang Y. Polymorphisms in DNA Repair Gene and Susceptibility to Glioma: A Systematic Review and Meta-Analysis Based on 33 Studies with 15 SNPs in 9 Genes. Cell Mol Neurobiol. 2016.
21. Adel Fahmideh M, Schwartzbaum J, Frumento P, Feychtig M. Association between DNA repair gene polymorphisms and risk of glioma: A systematic review and meta-analysis. Neuro Oncol. 2014.
22. Pabalan NA. Meta-analysis in cancer genetics. Asian Pac J Cancer Prev. 2010; 11: 33-8.
23. Rotondi MA, Bull SB. Cumulative meta-analysis for genetic association: when is a new study worthwhile? Hum Hered. 2012; 74: 61-70.

24. Kiuru A, Lindholm C, Heinavaara S, Ilus T, Jokinen P, Haapasalo H, Salminen T, Christensen HC, Feychtung M, Johansen C, Lonn S, Malmer B, Schoemaker MJ, et al. XRCC1 and XRCC3 variants and risk of glioma and meningioma. J Neurooncol. 2008; 88: 135-42.

25. Liu Y, Scheurer ME, El-Zein R, Cao Y, Do KA, Gilbert M, Aldape KD, Wei Q, Etzel C, Bondy ML. Association and interactions between DNA repair gene polymorphisms and adult glioma. Cancer Epidemiol Biomarkers Prev. 2009; 18: 204-14.

26. McKean-Cowdin R, Barnholtz-Sloan J, Inskip PD, Ruder AM, Butler M, Rajaraman P, Razavi P, Patoka J, Wiencke JK, Bondy ML, Wrensch M. Associations between polymorphisms in DNA repair genes and glioblastoma. Cancer Epidemiol Biomarkers Prev. 2009; 18: 1118-26.

27. Rajaraman P, Hutchinson A, Wichner S, Black PM, Fine HA, Loeffler JS, Selker RG, Shapiro WR, Rothman N, Linet MS, Inskip PD. DNA repair gene polymorphisms and risk of adult meningioma, glioma, and acoustic neuroma. Neuro Oncol. 2010; 12: 37-48.

28. Hu XB, Feng Z, Fan YC, Xiong ZY, Huang QW. Polymorphisms in DNA repair gene XRCC1 and increased genetic susceptibility to glioma. Asian Pac J Cancer Prev. 2011; 12: 2981-4.

29. Zhou LQ, Ma Z, Shi XF, Yin XL, Huang KK, Jiu ZS, Kong WL. Polymorphisms of DNA repair gene XRCC1 and risk of glioma: a case-control study in southern China. Asian Pac J Cancer Prev. 2011; 12: 2547-50.

30. Custodio AC, Almeida LO, Pinto GR, Santos MJ, Almeida JR, Clara CA, Rey JA, Casartelli C. Variation in DNA repair gene XRCC3 affects susceptibility to astrocytomas and glioblastomas. Genet Mol Res. 2012; 11: 332-9.

31. Liu HB, Peng YP, Dou CW, Su XL, Gao NK, Tian FM, Bai J. Comprehensive study on associations between nine SNPs and glioma risk. Asian Pac J Cancer Prev. 2012; 13: 4905-8.

32. Wang D, Hu Y, Gong H, Li J, Ren Y, Li G, Liu A. Genetic polymorphisms in the DNA repair gene XRCC1 and susceptibility to glioma in a Han population in northeastern China: a case-control study. Gene. 2012; 509: 223-7.

33. Luo KQ, Mu SQ, Wu ZX, Shi YN, Peng JC. Polymorphisms in DNA repair genes and risk of glioma and meningioma. Asian Pac J Cancer Prev. 2013; 14: 449-52.

34. Pan WR, Li G, Guan JH. Polymorphisms in DNA repair genes and susceptibility to glioma in a Chinese population. Int J Mol Sci. 2013; 14: 3314-24.

35. Xu G, Wang M, Xie W, Bai X. Three polymorphisms of DNA repair gene XRCC1 and the risk of glioma: a case-control study in northwest China. Tumour Biol. 2014; 35: 1389-95.

36. Liu Y. (2007). Association between DNA double-strand break repair pathway gene polymorphism and genetic susceptibility to glioma. Genetics, College of Life Science. (Shanghai: Fudan University). pp. 120.

37. Gao K, Mu SQ, Wu ZX. Investigation of the effects of single-nucleotide polymorphisms in DNA repair genes on the risk of glioma. Genet Mol Res. 2014; 13: 1203-11.

38. Li J, Qu Q, Qu J, Luo WM, Wang SY, He YZ, Luo QS, Xu YX, Wang YF. Association between XRCC1 polymorphisms and glioma risk among Chinese population. Med Oncol. 2014; 31: 186.

39. Fan SC, Zhou JG, Yin JZ. Investigation of the role of XRCC1 genetic polymorphisms in the development of gliomas in a Chinese population. Genet Mol Res. 2016; 15.

40. Leng WD, He MN, Chen QL, Gong H, Zhang L, Zeng XT. Vascular endothelial growth factor (VEGF) gene polymorphisms and risk of head and neck cancer: a meta-analysis involving 2,444 individuals. Mol Biol Rep. 2013; 40: 5987-92.

41. Mao M, Zeng XT, Ma T, He W, Zhang C, Zhou J. Interleukin-1alpha -899 (+4845) C-->T polymorphism increases the risk of chronic periodontitis: evidence from a meta-analysis of 23 case-control studies. Gene. 2013; 532: 114-9.

42. Xu C, Zeng XT, Liu TZ, Zhang C, Yang ZH, Li S, Chen XY. Fruits and Vegetables Intake and Risk of Bladder Cancer: A PRISMA-Compliant Systematic Review and Dose-Response Meta-Analysis of Prospective Cohort Studies. Medicine (Baltimore). 2015; 94: e759.

43. Zeng XT, Leng WD, Zhang C, Liu J, Cao SY, Huang W. Meta-analysis on the association between toothbrushing and head and neck cancer. Oral Oncol. 2015; 51: 446-51.

44. Zeng X, Zhang Y, Kwong JS, Zhang C, Li S, Sun F, Niu Y, Du L. The methodological quality assessment tools for preclinical and clinical studies, systematic review and meta-analysis, and clinical practice guideline: a systematic review. J Evid Based Med. 2015; 8: 2-10.

45. Curry WT Jr, Barker FG 2nd. Racial, ethnic and socioeconomic disparities in the treatment of brain tumors. J Neurooncol. 2009; 93: 25-39.

46. Trikalinos TA, Salanti G, Khoury MJ, Ioannidis JP. Impact of violations and deviations in Hardy-Weinberg equilibrium on postulated gene-disease associations. Am J Epidemiol. 2006; 163: 300-9.

47. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009; 339: b2535.

48. Huedo-Medina TB, Sanchez-Meca J, Marin-Martinez F, Botella J. Assessing heterogeneity in meta-analysis: Q statistic or I2 index? Psychol Methods. 2006; 11: 193-206.

49. Deeks JJ, Higgins JP, Altman DG. (2011). 9.5 Heterogeneity > 9.5.2 Identifying and measuring heterogeneity. In: Higgins JP and Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions: The Cochrane Collaboration.

50. Yan Y, Weng H, Shen ZH, Wu L, Zeng XT. Association between interleukin-4 gene -590 c/t, -33 c/t, and
70-base-pair polymorphisms and periodontitis susceptibility: a meta-analysis. J Periodontol. 2014; 85: e354-62.

51. Zeng XT, Luo W, Geng PL, Guo Y, Niu YM, Leng WD. Association between the TP53 codon 72 polymorphism and risk of oral squamous cell carcinoma in Asians: a meta-analysis. BMC Cancer. 2014; 14: 469.

52. Chen YJ, Han Y, Mao M, Tan YQ, Leng WD, Zeng XT. Interleukin-1beta rs1143634 polymorphism and aggressive periodontitis susceptibility: a meta-analysis. Int J Clin Exp Med. 2015; 8: 2308-16.

53. Zeng XT, Liu DY, Kwong JS, Leng WD, Xia LY, Mao M. Meta-Analysis of Association Between Interleukin-1beta C-511T Polymorphism and Chronic Periodontitis Susceptibility. J Periodontol. 2015; 86: 812-9.

54. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997; 315: 629-34.